Psychedelics PharmAla Biotech lists on the OTCQB middle-tier venture market The MDMA producer is now trading under the symbol PMBHF, which is intended to attract more investors in the U.S. Rowan DunneSeptember 6, 2023
Psychedelics Otsuka Pharmaceutical seals $80M all-cash deal to acquire Mindset Pharma Mindset shareholders will receive $0.75 in cash for each share, representing a premium based on various trading metrics Natalia Buendia CalvilloAugust 31, 2023
News Silo Wellness to acquire NUGL/Kaya Group in a $43.3M deal Silo Wellness will acquire all of NUGL's issued and outstanding shares in exchange for 2 million shares from its treasury Natalia Buendia CalvilloAugust 30, 2023
Psychedelics Cybin inks agreement to acquire DMT drug developer Small Pharma The companies say they will have the most substantial dataset on the DMT molecule in the industry and largest IP portfolio Rowan DunneAugust 28, 2023
News New research affirms therapists as pivotal for success in psilocybin-assisted therapy The research could have far-reaching implications for the training of therapists and the delivery of psychedelic therapies in clinical settings Natalia Buendia CalvilloAugust 28, 2023
News CBSA busts 3.3 tonnes of chemicals used to manufacture MDMA When ingested, 1,4-butanediol produces an effect that is not unlike that of Gamma-Hydroxybutyrate (GHB) Natalia Buendia CalvilloAugust 24, 2023
News Psychedelics may help athletes’ mental health: UoT professor Poor mental health affects not only quality of life but performance, resilience and career trajectories of athletes Natalia Buendia CalvilloAugust 23, 2023
Psychedelics Filament Health gets FDA approval for psilocybin studies on cancer-related anxiety and depression The clinical trials will examine the effects of the company's botanical psilocybin drug candidate PEX010 Rowan DunneAugust 10, 2023
News American Psychedelic Practitioners Association and BrainFutures release psychedelic-assisted therapy guidelines The model combines the use of a psychedelic medication with therapy in a single session Natalia Buendia CalvilloAugust 9, 2023
Psychedelics Cybin reaches end of psilocybin analogue clinical trial for depression CYB003 is a molecule developed by the company with rapid onset and a short duration Rowan DunneAugust 3, 2023